Aerocrine and Meditab partner for Allergy offices across the US.

Mar 16 2011

Aerocrine AB (OMX Nordic Exchange: AERO)(STO:AEROB) today announced the launch of a strategic alliance with Meditab Software Inc. at the American Association of Allergy, Asthma and Immunology annual meeting in San Francisco on March 19-21.

Aerocrine and Meditab join forces for the Allergy offices across the US. Meditab, based in northern California, is an industry leader in providing fully integrated and certified electronic health records and practice management solutions for physicians throughout the US. They supply a unique electronic medical records (EMR) product for the Allergists, a primary call point for Aerocrine, that will now also comprise measurements of airway inflammation performed with NIOX MINO.

"Meditab Software has always been dedicated in providing unique features in its medical software products to increase the productivity of clinical staff and to improve patient safety. As a leader in providing a complete solution for Allergists and Pulmonologists, we are very excited to offer an integration with Aerocrine's NIOX MINO. This integration will allow the providers to accurately record and trend FENO data directly within the electronic medical records to improve patient outcome," said Kal Patel, Meditab's Chief Operating Officer.

"Aerocrine's revolutionary technology of measuring airway inflammation in asthma management is gaining rapid acceptance with Allergists," said Kathy Hodgdon, Aerocrine Inc's Director of Sales and Marketing. "The ability to directly transfer test results into the patient's electronic medical record is valuable and now this can be achieved by the Meditab alliance."

Asthma is a chronic inflammatory disease where an inflammation of the airways causes increased sensitivity to asthma triggers. The disease affects more than 22 million Americans, including more than six million children. Aerocrine's founders made the original discovery that levels of nitric oxide in exhaled breath, FENO, is elevated in patients with asthma. The company has since pioneered the development of medical devices to monitor airway inflammation by measuring FENO. NIOX MINO, the first handheld device for FENO monitoring in clinical practice, received FDA clearance in 2008. To date, more than four million patient tests have been performed around the world using Aerocrine's NIOX products.